Cargando…
Is there a role for tedizolid in the treatment of non-tuberculous mycobacterial disease?
BACKGROUND: Pulmonary infections caused by non-tuberculous mycobacteria (NTM) are hard to treat and have low cure rates despite intensive multidrug therapy. OBJECTIVES: To assess the feasibility of tedizolid, a new oxazolidinone, for the treatment of Mycobacterium avium and Mycobacterium abscessus....
Autores principales: | Ruth, Mike Marvin, Koeken, Valerie A C M, Pennings, Lian J, Svensson, Elin M, Wertheim, Heiman F L, Hoefsloot, Wouter, van Ingen, Jakko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7021090/ https://www.ncbi.nlm.nih.gov/pubmed/31886864 http://dx.doi.org/10.1093/jac/dkz511 |
Ejemplares similares
-
Prolonged tedizolid use in cutaneous non-tuberculous mycobacterial infection
por: Shaw, Timothy David, et al.
Publicado: (2021) -
The epidemiology of nontuberculous mycobacterial pulmonary disease in the Netherlands
por: Schildkraut, Jodie Anne, et al.
Publicado: (2021) -
Mycobacterium Growth Indicator Tube Time-To-Positivity Can Serve As an Early Biomarker of Treatment Response in Mycobacterium avium Complex Pulmonary Disease
por: Danho, Rabi, et al.
Publicado: (2022) -
Inhaled tigecycline is effective against Mycobacterium abscessus in vitro and in vivo
por: Pearce, Camron, et al.
Publicado: (2020) -
The role of rifampicin within the treatment of Mycobacterium avium pulmonary disease
por: Schildkraut, Jodie A., et al.
Publicado: (2023)